A new paper from Shoukhrat Mitalipov’s lab on stem cell mitochondria points to a pattern whereby induced pluripotent stem (IPS) cells tend to have more problems if they are from older patients. What does this paper mean for the stem cell field and could it impact more specifically the clinical applications of IPS cells? The new …
New Mitalipov paper on stem cell mitochondria: challenge for IPS cell field? Read More »
In a new, thought-provoking paper today in Nature, Shoukhrat Mitalipov and a multi-institutional team report a significant advance toward potential novel ways to treat mitochondrial diseases. What are these illnesses? Mitochondrial diseases are rare, but devastating disorders caused by genetic mutations. Today they are largely impossible to treat in meaningful ways other than palliative care. Some …
Mitalipov Nature pub review: IPSC & SCNT for mitochondrial disease Read More »
Remember that old TV show the Odd Couple with very proper Felix Unger and his polar opposite Oscar Madison who has all kinds of baggage? They’ve cloned it into a remake to be on TV soon here in the US in 2015. It seems only fitting then that actual human cloning research has a new …
The Odd Couple of Cloning Research: Mitalipov & Woo Suk Hwang Unite Read More »
Just how good are human embryonic stem (ES) cells made by therapeutic cloning via nuclear transfer, with the successful technique first reported by the lab of Shoukhrat Mitalipov at OHSU last year? How do they compare to induced pluripotent stem (iPS) cells or traditional ES cells made from IVF embryos? A new paper in Nature directly tackles these …
Review of Mitalipov Nature paper: cloned ES cells vs iPS cells Read More »
People have been confused about human cloning issues in the last few weeks on a number of levels. The confusion has come along with the excitement, concern, and increased interest in cloning lately since the lab of Dr. Shoukhrat Mitalipov reported a few weeks back in Cell the astonishing feat of successful human embryonic stem …
The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on …
Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »
My to-read list this weekend includes a range of papers along with various news & media including a report of two US research groups aiming to get CRISPR baby patents. More on that below. At long last a trip + fun thing to do in NYC Last week I took my first trip in more …
Weekly reads: escape to New York, CRISPR baby patents, ISSCR guidelines, pubs Read More »
Three new studies reported in preprints all show severe DNA damage to human embryos from CRISPR a surprisingly high percentage of the time including in some cases loss of heterozygosity (LOH). Anywhere from about a quarter to half of CRISPR’d embryos exhibited major genome damage. As readers of The Niche know, I never was a …
Two prominent scientists, Robin Lovell-Badge and George Daley, have been amongst the most outspoken proponents of leaving the door open to heritable human genetic modification via CRISPR. While they each have articulated their reasons in somewhat different ways at times, their core reasons arguing in favor of future heritable CRISPR appear largely the same. In …
Counterpoints to Lovell-Badge & Daley’s CRISPR baby rationales Read More »
Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or …
Good final grades on my 20 x 2018 stem cell predictions Read More »